1. Rajasalu T, Vilimaa T. Suhkurtõve levimus eesti täiskasvanud rahvastikus [The prevalence of diabetes in the Estonian adult population]. Eesti Arst. 2008;87:337–41.
2. Eglit T, Rajasalu T, Lember M. Prevalence of diabetes and impaired glucose regulation in Estonia. Diabet Med. 2011;28(4):504–5.
3. National Institute for Health Development. Tervisestatistika ja terviseuuringute andmebaas [Health Statistics and Health Research Database]. Esmashaigusjuhud soo ja vanuserühma järgi [Primary cases by gender and age group]. 2017.
http://pxweb.tai.ee/PXWeb2015/pxweb/et/02Haigestumus
. Accessed 14 Sep 2018.
4. Juus E, Volke V, Roosimaa M, Lutsar K, Lukka M, Kiivet R. Tervisetehnoloogia hindamise raport TTH33: GLP-1 retseptori agonistide kliiniline tõenduspõhisus ja kulutõhusus 2. tüüpi diabeedi ravis [Health Technology Assessment Report TTH33: The clinical evidence-based and cost-effectiveness of GLP-1 receptor agonists in the treatment of type 2 diabetes]. 2017.
https://tervis.ut.ee/en/health-technology-assessment/hta-reports
. Accessed 2 Apr 2018.
5. International Diabetes Federation. Diabetes atlas, 8th edn. 2017.
http://www.diabetesatlas.org/across-the-globe.html
. Accessed 20 Aug 2018.